Workflow
Boston Scientific(BSX)
icon
Search documents
Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock
ZACKS· 2025-06-10 13:55
Key Takeaways Boston Scientific is gaining from rapid growth in cardiovascular devices, led by EP and heart products. BSX sees strong global traction for FARAPULSE and 24% WATCHMAN sales growth in Q1 2025. The Zacks Consensus Estimate for BSX's 2025 sales and EPS is rising on strong demand and operating resilience.Boston Scientific (BSX) , a prominent global player in cardiovascular technology, is well-positioned to capitalize on the robust expansion of the cardiovascular devices market. According to a Ma ...
Boston Scientific (BSX) Upgraded to Buy: Here's Why
ZACKS· 2025-06-06 17:01
Boston Scientific (BSX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individual ...
Emerging Markets Power Boston Scientific: Will the Growth Trend Continue?
ZACKS· 2025-06-04 14:06
Key Takeaways Boston Scientific saw 9.8% operational sales growth in emerging markets in Q1 2025 despite geopolitical risks. BSX benefits from favorable economic trends, healthcare infrastructure and sustained investment. BSX competes with ABT and MDT, which also report strong emerging market growth and localization efforts.Emerging markets remain a vital growth engine for Boston Scientific Corporation (BSX) , anchoring the company’s broader international strategy and long-term expansion plans. In the fir ...
Boston Scientific: Old, Reliable; Buy For Their Consistent Growth
Seeking Alpha· 2025-05-30 08:45
Industry Overview - The medical device industry is central to delivering effective healthcare outcomes through advanced technology and engineering [1] - Key innovations include minimally invasive surgical tools, wearable technologies, and enhanced robotic capabilities [1] Company Highlights - Several standout companies are leading the advancements in the medical device sector [1]
Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook
Benzinga· 2025-05-28 19:40
Boston Scientific Corporation BSX is pulling the plug on its ACURATE neo2 and Prime aortic valve systems.What Happened: The medical technology giant halted global sales and abandoned regulatory pursuits—including a long-sought FDA approval—after escalating demands from health authorities rendered the effort too costly. Despite the setback, the Marlborough, Massachusetts-based company signaled confidence in its broader portfolio, affirming that it remains on track to hit its financial targets for the quarter ...
Boston Scientific Corporation (BSX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Seeking Alpha· 2025-05-28 16:14
Boston Scientific Corporation (NYSE:BSX) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 8:01 AM ET Company Participants Michael Mahoney - Chairman and Chief Executive Officer Kenneth Stein - Senior Vice President and Global Chief Medical Officer Conference Call Participants Lee Hambright - Sanford C. Bernstein & Co., LLC Lee Hambright Okay. Thanks, everybody, for coming. I'm Lee Hambright, U.S. medtech analyst at Bernstein. We are very pleased to host Boston Scientific today. We've g ...
Boston Scientific(BSX) - 2025 FY - Earnings Call Transcript
2025-05-28 13:00
Boston Scientific (BSX) FY 2025 Conference May 28, 2025 08:00 AM ET Speaker0 Thanks everybody for coming. I'm Lee Hambrite, US med tech analyst at Bernstein. We are very pleased to host Boston Scientific today. We've got chairman and CEO Mike Mahoney Speaker1 and chief medical officer doctor Ken Stein. Thanks so much guys for being here. Pleasure. For those of you in the audience, if you would like to ask a question, you could submit it via the pigeonhole tool, and I will try to work in as many as I can her ...
Boston Scientific (BSX) Up 3.3% Since Last Earnings Report: Can It Continue?
ZACKS· 2025-05-23 16:37
Core Viewpoint - Boston Scientific shares have increased by approximately 3.3% over the past month, underperforming the S&P 500 index [1] Group 1: Earnings and Estimates - Estimates for Boston Scientific have trended upward in the past month, indicating positive sentiment among analysts [2] - The most recent earnings report highlighted important drivers for the stock's performance [1] Group 2: VGM Scores - Boston Scientific has a Growth Score of B, a Momentum Score of C, and a Value Score of D, placing it in the bottom 40% for the value investment strategy [3] - The aggregate VGM Score for Boston Scientific is C, which is relevant for investors not focused on a single strategy [3] Group 3: Outlook - The upward trend in estimates suggests a promising outlook for Boston Scientific, with a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [4] Group 4: Industry Performance - Boston Scientific is part of the Zacks Medical - Products industry, where Abbott has gained 1.6% over the past month [5] - Abbott reported revenues of $10.36 billion for the last quarter, reflecting a year-over-year increase of 4%, with EPS rising from $0.98 to $1.09 [5] - For the current quarter, Abbott is expected to post earnings of $1.25 per share, representing a 9.7% increase from the previous year [6]
Is it Worth Retaining Boston Scientific Stock in Your Portfolio Now?
ZACKS· 2025-05-14 12:15
Core Viewpoint - Boston Scientific's first-quarter 2025 performance is characterized by strong international expansion and strategic acquisitions, although it faces challenges from currency fluctuations and competitive pressures [1][10]. Group 1: Financial Performance - In the past year, Boston Scientific's shares have increased by 40%, outperforming the industry and S&P 500, which grew by 10.2% and 11.2% respectively [2]. - The company has a market capitalization of $152.31 billion and has consistently beaten earnings expectations over the last four quarters, with an average surprise of 8.79% [2]. - The Zacks Consensus Estimate for Boston Scientific's 2025 earnings per share has increased by 2.1% to $2.91, while the revenue estimate is projected at $19.49 billion, reflecting a 16.4% increase year-over-year [12]. Group 2: International Expansion - Boston Scientific is actively expanding its operations in international markets, particularly in emerging markets, which show strong growth potential due to favorable economic conditions and healthcare sector developments [3]. - In the first quarter of 2025, emerging markets reported a nearly 9.8% year-over-year growth in net sales on an operational basis [4]. - The Europe, Middle East, and Africa (EMEA) region saw an 8% year-over-year sales growth, driven by strong performance in electrophysiology and double-digit growth in key technologies [5]. - In the Asia Pacific (APAC) region, Japan experienced double-digit growth, while China achieved high single-digit growth despite a challenging comparison from the previous year [6]. Group 3: Strategic Acquisitions - Recent acquisitions by Boston Scientific, including Bolt Medical and Cortex, are expected to enhance the company's product offerings and long-term revenue growth [7]. - The company is also in the process of acquiring SoniVie and Intera Oncology, which will expand its capabilities in renal denervation and interventional oncology, respectively [8]. Group 4: Challenges - Boston Scientific is significantly exposed to currency fluctuations, with 40% of its sales coming from international markets, which has negatively impacted its performance in recent quarters [10]. - The medical devices market is highly competitive, with Boston Scientific facing challenges from both large, well-capitalized companies and smaller players across various segments [11].
Boston Scientific Corporation (BSX) Bank of America's 2025 Health Care Conference (Transcript)
Seeking Alpha· 2025-05-13 19:33
Core Insights - Boston Scientific Corporation has experienced significant stock performance, with a 750% increase since January 1, 2014, compared to the S&P's 285% increase during the same period, resulting in an annual return of nearly 21% for Boston Scientific [5]. Company Performance - The company has created substantial shareholder value, outperforming the healthcare sector, which returned 10%, and the S&P, which returned 12.6% [5]. Leadership Transition - Daniel Brennan, the current CFO, is transitioning out, and there is a succession plan in place with John as the successor. The expectation is that there will not be significant changes with this transition [7].